We discover and develop revolutionary treatments for neurodegenerative diseases

Couple.png

We’re in the business of offering new hope.

Neuraly was founded to develop new drugs that change our expectations about successful treatment of progressive diseases like Alzheimer’s and Parkinson’s. We are developing drugs that address new pathways, capitalize on our founder’s innovation, and deliver medicines with the potential to change lives.

TheScience.png

Our Scientific Platform

Read about the science behind our approach to treating neurodegenerative diseases.

Learn More

 
Pipeline1.png

Our Pipeline

Our clinical development strategy focuses on the inhibition of pathological glial activation and its role in preventing neuronal cell death.

View Programs

 
Science 1.png

Our efforts are the work of many hands.

Our world-class team is composed of innovators and trailblazers, committed to finding a cure where no disease-modifying therapies exist.

thisisengineering-raeng-vGA1ei1yxos-unsplash2.png

Join a team that lives to improve lives.

From the beginning, Neuraly has been a team of dedicated and passionate professionals. We pride ourselves on a culture of curiosity and creative problem solving as we leap toward a future where people with severe neurodegenerative diseases are living fulfilled lives. Eager to join us on our journey?

Neuraly in the News

March 27, 2023

Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson’s Disease

Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced topline results from the Phase 2 trial with NLY01 in patients with early, untreated Parkinson’s disease (PD).

Full Article

April 19, 2022

Neuraly Announces Completion of Enrollment in Phase 2 Clinical Trial of NLY01 in Patients with Parkinson’s Disease

Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the completion of patient enrollment in its Phase 2 study of NLY01 for Parkinson’s disease (PD).

Full Article

Jan 28, 2022

How the Prism Parkinson’s Research Study Might Change the Way We Treat Parkinson’s

Three times in history, the stars aligned to create an environment in which a Parkinson’s breakthrough therapy was possible. 

The first was in 1960, when scientists first realized that dopamine was linked to Parkinson’s — a realization that helped researchers discover how levodopa could treat symptoms. 

Full Article